Author pages are created from data sourced from our academic publisher partnerships and public sources.
- Publications
- Influence
[Phase I clinical trial of RP 56976 (docetaxel) a new anticancer drug].
- T. Taguchi, H. Furue, +7 authors M. Fukuoka
- Medicine
- Gan to kagaku ryoho. Cancer & chemotherapy
- 1 September 1994
A multicenter phase I clinical trial of RP 56976 (docetaxel), a new anticancer drug, was performed with single and repeated doses. Based on the results of phase I clinical trials conducted in the… Expand
[Phase I clinical study of CPT-11. Research group of CPT-11].
- T. Taguchi, Akira Wakui, +4 authors T. Hattori
- Medicine
- Gan to kagaku ryoho. Cancer & chemotherapy
- 1990
CPT-11 is a new derivative of Camptothecin. Phase I clinical study of single administration with CPT-11 was carried out by a cooperative study group. Starting from 50 mg/m2 (n), dose was escalated to… Expand
[A late phase II clinical study of RP56976 (docetaxel) in patients with advanced or recurrent gastric cancer: a cooperative study group trial (group B)].
- M. Mai, Y. Sakata, +6 authors H. Furue
- Medicine
- Gan to kagaku ryoho. Cancer & chemotherapy
- 1 March 1999
A late phase II clinical study of RP56976 (docetaxel) in patients with advanced or recurrent gastric cancer was performed to evaluate the anti-tumor activity and clinical toxicity as a multicenter… Expand
[Phase I study of S-1. S-1 Study Group].
- T. Taguchi, Y. Inuyama, +19 authors I. Nakao
- Medicine
- Gan to kagaku ryoho. Cancer & chemotherapy
- 1 December 1997
We have conducted Phase I study of a novel oral antitumor agent of fluorinated pyrimidines, S-1, in which tegafur (FT) is combined with two classes of modulator, 5-chloro-2,4-dihydroxypyridine (CDHP)… Expand
Phase I study of recombinant human tumor necrosis factor
- K. Kimura, T. Taguchi, +15 authors The A-TNF Cooperative Study Group
- Medicine
- Cancer Chemotherapy and Pharmacology
- 2004
SummaryA phase I clinical and pharmacokinetic study of recombinant human tumor necrosis factor (rH-TNF) was conducted in a single dose schedule in 33 patients with advanced cancer. rH-TNF was given… Expand
Adrenal myelolipoma associated with congenital adrenal 21-hydroxylase deficiency.
- C. Murakami, M. Ishibashi, +7 authors T. Yamaji
- Medicine
- Internal medicine
- 1 June 1992
The occurrence of adrenal myelolipomas is reported in an untreated patient with congenital adrenal 21-hydroxylase deficiency. Laparotomy demonstrated the presence of two lesions, a large tumor which… Expand
Treatment of adult T‐cell leukemia/lymphoma with MST‐16, a new oral antitumor drug and a derivative of bis(2,6‐dioxopiperazine)
- R. Ohno, T. Masaoka, +9 authors H. Furue
- Medicine
- Cancer
- 1 April 1993
Background. MST‐16, a new orally administered bis(2,6‐dioxopiperazine) analogue and an inhibitor of topoisomerase II, was given to 24 patients with adult T‐cell leukemia‐lymphoma (ATLL) in a Phase… Expand
Clinical efficacy of lentinan on neoplastic diseases.
- T. Taguchi, H. Furue, T. Kimura, T. Kondo, T. Hattori, N. Ogawa
- Medicine
- Advances in experimental medicine and biology
- 1983
Lentinan, a β-(1-3)-glucan with some β-(1-6)-gluco-pyranoside branchings, has been extracted and purified from Lentinus edodes a most popular edible mushroom in Japan. This substance has been shown… Expand
[Studies on the application of microexplosion to medicine and biology. II. Construction and strength of urinary calculi (author's transl)].
- S. Murata, H. Watanabe, T. Takahashi, K. Watanabe, H. Furue
- Medicine
- Nihon Hinyokika Gakkai zasshi. The japanese…
- 1 March 1977
Spontaneous remission in Cushing's disease.
- M. Ishibashi, K. Shimada, K. Abe, H. Furue, T. Yamaji
- Medicine
- Archives of internal medicine
- 25 January 1993
Two patients with Cushing's disease underwent spontaneous clinical and biochemical remission following a period of secondary adrenal insufficiency. One of the patients was untreated, while the other… Expand